NeuroBo Pharmaceuticals Reports Full Year 2022 Financial Results

Provided By PR Newswire

Last update: Mar 30, 2023

Company Pipeline to Focus on Cardiometabolic Disease

Cash and Cash Equivalents to Fund the Company into 2024

BOSTON, March 30, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company primarily focused on cardiometabolic diseases, today announced financial results for the year ended December 31, 2022.